3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Other solid neoplasm
2
Gynecologic
2
Breast
2
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
62
Paclitaxel
51
Gemcitabine
50
Carboplatin
45
Docetaxel
43
Cisplatin
31
Pemetrexed
30
Nivolumab
28
Bevacizumab
28
atezolizumab
22
Fluorouracil
22
Cetuximab
21
Capecitabine
21
Irinotecan
20
Leucovorin
19
Afatinib
18
Erlotinib Hydrochloride
15
trametinib
14
Trastuzumab
13
Ipilimumab
13
130-nm albumin-bound paclitaxel
13
regorafenib
11
olaparib
11
Sorafenib
11
Oxaliplatin
11
Drug Therapy
11
eribulin
10
enzalutamide
10
Midazolam
10
Injections
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
MK 2206
×
Tumor-Agnostic
×
Clear all
NCT00848718
2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1
Completed
77 enrolled
24 charts
NCT00670488
2019-04-01
MK-2206-002
Merck Sharp & Dohme LLC
Phase 1
Completed
104 enrolled
28 charts